Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Eli Lilly and Company has announced positive topline Phase 3 results from Achieve-1, evaluating the safety and efficacy of ...

Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report ...

For some patients, injectables, such as insulin or a glucagon-like peptide-1 (GLP-1) receptor agonist, need to be utilized. Mounjaro was approved by the Food and Drug Administration (FDA ...